BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 21954603)

  • 1. [Thermodynamics of calmodulin and tubulin binding to the vinca-alkaloid vinorelbine].
    Tsvetkov FO; Kulikova AA; Devred F; Zerniĭ EIu; Lafitte D; Makarov AA
    Mol Biol (Mosk); 2011; 45(4):697-702. PubMed ID: 21954603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction of vinca alkaloids with tubulin: a comparison of vinblastine, vincristine, and vinorelbine.
    Lobert S; Vulevic B; Correia JJ
    Biochemistry; 1996 May; 35(21):6806-14. PubMed ID: 8639632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Energetics of vinca alkaloid interactions with tubulin.
    Lobert S; Correia JJ
    Methods Enzymol; 2000; 323():77-103. PubMed ID: 10944748
    [No Abstract]   [Full Text] [Related]  

  • 4. Theoretical insight into the structural mechanism for the binding of vinblastine with tubulin.
    Chi S; Xie W; Zhang J; Xu S
    J Biomol Struct Dyn; 2015; 33(10):2234-54. PubMed ID: 25588192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vinflunine, a novel microtubule inhibitor, suppresses calmodulin interaction with the microtubule-associated protein STOP.
    Makarov AA; Tsvetkov PO; Villard C; Esquieu D; Pourroy B; Fahy J; Braguer D; Peyrot V; Lafitte D
    Biochemistry; 2007 Dec; 46(51):14899-906. PubMed ID: 18052208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. QM and QM/MD simulations of the Vinca alkaloids docked to tubulin.
    Kelly EB; Tuszynski JA; Klobukowski M
    J Mol Graph Model; 2011 Sep; 30():54-66. PubMed ID: 21798777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid.
    Kruczynski A; Barret JM; Etiévant C; Colpaert F; Fahy J; Hill BT
    Biochem Pharmacol; 1998 Mar; 55(5):635-48. PubMed ID: 9515574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BM6, a new semi-synthetic vinca alkaloid, exhibits its potent in vivo anti-tumor activities via its high binding affinity for tubulin and improved pharmacokinetic profiles.
    Li W; Shao Y; Hu L; Zhang X; Chen Y; Tong L; Li C; Shen X; Ding J
    Cancer Biol Ther; 2007 May; 6(5):787-94. PubMed ID: 17387272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elaboration of simplified vinca alkaloids and phomopsin hybrids.
    Ngo QA; Roussi F; Thoret S; Guéritte F
    Chem Biol Drug Des; 2010 Mar; 75(3):284-94. PubMed ID: 20659111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Energetics of vinca alkaloid interactions with tubulin isotypes: implications for drug efficacy and toxicity.
    Lobert S; Frankfurter A; Correia JJ
    Cell Motil Cytoskeleton; 1998; 39(2):107-21. PubMed ID: 9484953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism of mitotic block and inhibition of cell proliferation by the semisynthetic Vinca alkaloids vinorelbine and its newer derivative vinflunine.
    Ngan VK; Bellman K; Hill BT; Wilson L; Jordan MA
    Mol Pharmacol; 2001 Jul; 60(1):225-32. PubMed ID: 11408618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and biological evaluation of C-13' substituted 7'-homo-anhydrovinblastine derivatives.
    Gherbovet O; La Spisa F; Thoret S; Alvarez MCG; Levaique H; Bignon J; Roussi F
    Bioorg Med Chem Lett; 2015 Apr; 25(8):1771-1773. PubMed ID: 25804719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel aspects of natural and modified vinca alkaloids.
    Duflos A; Kruczynski A; Barret JM
    Curr Med Chem Anticancer Agents; 2002 Jan; 2(1):55-70. PubMed ID: 12678751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tubulin-based structure-affinity relationships for antimitotic Vinca alkaloids.
    Coderch C; Morreale A; Gago F
    Anticancer Agents Med Chem; 2012 Mar; 12(3):219-25. PubMed ID: 22044006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel actions of the antitumor drugs vinflunine and vinorelbine on microtubules.
    Ngan VK; Bellman K; Panda D; Hill BT; Jordan MA; Wilson L
    Cancer Res; 2000 Sep; 60(18):5045-51. PubMed ID: 11016627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular docking and pharmacogenomics of vinca alkaloids and their monomeric precursors, vindoline and catharanthine.
    Sertel S; Fu Y; Zu Y; Rebacz B; Konkimalla B; Plinkert PK; Krämer A; Gertsch J; Efferth T
    Biochem Pharmacol; 2011 Mar; 81(6):723-35. PubMed ID: 21219884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of thermodynamic parameters for vinorelbine- and vinflunine-induced tubulin self-association by sedimentation velocity.
    Lobert S; Ingram JW; Hill BT; Correia JJ
    Mol Pharmacol; 1998 May; 53(5):908-15. PubMed ID: 9584218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and tolerability of vinorelbine in the cancer therapy.
    Galano G; Caputo M; Tecce MF; Capasso A
    Curr Drug Saf; 2011 Jul; 6(3):185-93. PubMed ID: 22122393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential in vitro association of vinca alkaloid-induced tubulin spiral filaments into aggregated spirals.
    Verdier-Pinard P; Garès M; Wright M
    Biochem Pharmacol; 1999 Sep; 58(6):959-71. PubMed ID: 10509748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and evaluation of hybrid molecules targeting the vinca domain of tubulin.
    Gherbovet O; Sánchez-Murcia PA; García Alvarez MC; Bignon J; Thoret S; Gago F; Roussi F
    Org Biomol Chem; 2015 Mar; 13(10):3144-54. PubMed ID: 25634805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.